These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP. JAMA Oncol; 2018 Dec 01; 4(12):e184060. PubMed ID: 30383140 [Abstract] [Full Text] [Related]
17. Large esophageal gastrointestinal stromal tumors resected thoracoscopically after oral imatinib therapy: a report of two cases. Kurosaki T, Hoshino I, Kuwayama N, Suitou H, Kano M, Tonooka T, Chiba S, Soda H, Nabeya Y, Takayama W. Clin J Gastroenterol; 2023 Apr 01; 16(2):136-141. PubMed ID: 36547850 [Abstract] [Full Text] [Related]
19. Management and outcome of gastrointestinal stromal tumors of the duodenum. Chung JC, Chu CW, Cho GS, Shin EJ, Lim CW, Kim HC, Song OP. J Gastrointest Surg; 2010 May 01; 14(5):880-3. PubMed ID: 20140534 [Abstract] [Full Text] [Related]
20. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Farag S, Somaiah N, Choi H, Heeres B, Wang WL, van Boven H, Nederlof P, Benjamin R, van der Graaf W, Grunhagen D, Boonstra PA, Reyners AK, Gelderblom H, Steeghs N. Eur J Cancer; 2017 May 01; 76():76-83. PubMed ID: 28284172 [Abstract] [Full Text] [Related] Page: [Next] [New Search]